Compare YHC & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | PPBT |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.4M |
| IPO Year | 2023 | 2014 |
| Metric | YHC | PPBT |
|---|---|---|
| Price | $1.39 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.9K | 41.9K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.28 | N/A |
| Revenue | ★ $1,120,622.00 | N/A |
| Revenue This Year | $1,254.00 | N/A |
| Revenue Next Year | $21.74 | N/A |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | ★ 86.42 | N/A |
| 52 Week Low | $0.02 | $0.41 |
| 52 Week High | $2.72 | $5.18 |
| Indicator | YHC | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 34.93 |
| Support Level | $1.24 | $1.16 |
| Resistance Level | $1.60 | $1.60 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.32 | -0.01 |
| Stochastic Oscillator | 47.22 | 14.81 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.